| Hormonal and reproductive studies | Lifetime | 12 | IT 2 | 99.79 |
| Sexual function and dysfunction studies | Lifetime | 7 | IT 2 | 99.75 |
| Sexual Differentiation and Disorders | Lifetime | 22 | IT 1 | 99.58 |
| Pharmacology and Obesity Treatment | Lifetime | 34 | IT 1 | 99.36 |
| Urinary Bladder and Prostate Research | Lifetime | 81 | IT 7 | 99.40 |
| Hypothalamic control of reproductive hormones | Lifetime | 90 | IT 4 | 98.58 |
| Sexuality, Behavior, and Technology | Lifetime | 140 | IT 5 | 97.85 |
| Sperm and Testicular Function | Lifetime | 466 | IT 25 | 98.10 |
| Pharmacological Effects and Assays | Lifetime | 236 | IT 8 | 96.74 |
| Ovarian function and disorders | Lifetime | 580 | IT 47 | 97.47 |
| Electrolyte and hormonal disorders | Lifetime | 415 | IT 11 | 96.39 |
| Neuroendocrine regulation and behavior | Lifetime | 775 | IT 22 | 96.88 |
| LGBTQ Health, Identity, and Policy | Lifetime | 946 | IT 18 | 90.59 |
| COVID-19 Impact on Reproduction | Lifetime | 930 | IT 77 | 86.23 |
| Marriage and Sexual Relationships | Lifetime | 453 | IT 9 | 78.56 |
| Male Reproductive Health Studies | Lifetime | 925 | IT 22 | 75.16 |
| Male Breast Health Studies | Lifetime | 401 | IT 50 | 71.42 |
| Doping in Sports | Lifetime | 568 | IT 15 | 70.40 |
| Hormonal and reproductive studies | 2021-2025 | 7 | IT 3 | 99.18 |
| Sexual function and dysfunction studies | 2021-2025 | 22 | IT 10 | 98.00 |
| Hypothalamic control of reproductive hormones | 2021-2025 | 12 | IT 2 | 96.80 |
| Ovarian function and disorders | 2021-2025 | 261 | IT 24 | 93.71 |
| Sperm and Testicular Function | 2021-2025 | 401 | IT 40 | 90.20 |
| Pharmacology and Obesity Treatment | 2021-2025 | 128 | IT 7 | 90.35 |
| Sexual Differentiation and Disorders | 2021-2025 | 182 | IT 28 | 89.26 |
| COVID-19 Impact on Reproduction | 2021-2025 | 494 | IT 44 | 87.65 |
| Reproductive Health and Technologies | 2021-2025 | 532 | IT 41 | 85.01 |
| Urinary Bladder and Prostate Research | 2021-2025 | 953 | IT 129 | 81.85 |
| Adrenal and Paraganglionic Tumors | 2021-2025 | 723 | IT 90 | 79.52 |
| Electrolyte and hormonal disorders | 2021-2025 | 465 | IT 26 | 72.72 |
| Urologic and reproductive health conditions | 2021-2025 | 980 | IT 154 | 70.47 |
| Sexuality, Behavior, and Technology | 2021-2025 | 804 | IT 35 | 72.16 |
| Menopause: Health Impacts and Treatments | 2021-2025 | 635 | IT 43 | 57.59 |
| Doping in Sports | 2021-2025 | 222 | IT 10 | 53.97 |
| Paraoxonase enzyme and polymorphisms | 2021-2025 | 181 | IT 18 | 38.03 |
